Novel antifungal compounds against Fusarium spp: A systematic review

IF 2.2 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica Pub Date : 2026-03-01 Epub Date: 2026-02-12 DOI:10.1016/j.eimc.2026.503109

Nury Alejandra de León , Neri Alejandro Álvarez-Villalobos , Gloria M. González , Rogelio de J. Treviño-Rangel , Alexandra M. Montoya

{"title":"Novel antifungal compounds against Fusarium spp: A systematic review","authors":"Nury Alejandra de León , Neri Alejandro Álvarez-Villalobos , Gloria M. González , Rogelio de J. Treviño-Rangel , Alexandra M. Montoya","doi":"10.1016/j.eimc.2026.503109","DOIUrl":null,"url":null,"abstract":"<div><div><em>Fusarium</em> spp. has increased in relevance due to its resistance, high mortality, increasing incidence, and low preventability. The scarce treatment options compelled the development of antifungals with novel mechanisms of action. We conducted a systematic review to report on novel compounds and their activity on <em>Fusarium</em> spp. We searched for terms related to novel antifungals against <em>Fusarium</em> across multiple databases, up to February 2024. From 622 articles, only 15 articles met the eligibility criteria. The antifungals reported were manogepix (10), olorofim (3), ibrexafungerp (1), and MGCD290 (1), evaluated against 480 <em>Fusarium</em> isolates. Manogepix MIC/MECs had broad ranges for most <em>Fusarium</em> species, with notable exceptions like <em>F. solani</em> (MEC: ≤0.12μg/mL) and <em>F. fujikuroi</em> (MEC: ≤0.25μg/mL). Olorofim could be a good candidate for fusariosis treatment based on <em>in vitro</em> activity. Ibrexafungerp and MGCD290 did not show good activity as monotherapy. Further work on applications and development of new treatments against the resistant <em>Fusarium</em> species is essential.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"44 3","pages":"Article 503109"},"PeriodicalIF":2.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X26000182","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Fusarium spp. has increased in relevance due to its resistance, high mortality, increasing incidence, and low preventability. The scarce treatment options compelled the development of antifungals with novel mechanisms of action. We conducted a systematic review to report on novel compounds and their activity on Fusarium spp. We searched for terms related to novel antifungals against Fusarium across multiple databases, up to February 2024. From 622 articles, only 15 articles met the eligibility criteria. The antifungals reported were manogepix (10), olorofim (3), ibrexafungerp (1), and MGCD290 (1), evaluated against 480 Fusarium isolates. Manogepix MIC/MECs had broad ranges for most Fusarium species, with notable exceptions like F. solani (MEC: ≤0.12 μg/mL) and F. fujikuroi (MEC: ≤0.25 μg/mL). Olorofim could be a good candidate for fusariosis treatment based on in vitro activity. Ibrexafungerp and MGCD290 did not show good activity as monotherapy. Further work on applications and development of new treatments against the resistant Fusarium species is essential.

Abstract Image

查看原文本刊更多论文

新型抗镰刀菌化合物的系统综述

镰刀菌因其耐药性、高死亡率、发病率增加和低可预防性而日益重要。稀缺的治疗方案迫使开发具有新的作用机制的抗真菌药。我们对新化合物及其对镰刀菌的活性进行了系统综述，并在多个数据库中检索了截至2024年2月的与新型镰刀菌抗真菌剂相关的术语。从622篇文章中，只有15篇文章符合资格标准。报道的抗真菌剂有mangepix（10）、olorofim(3)、ibrexafungerp(1)和MGCD290(1)，对480株镰刀菌进行了评价。mangepix对大多数镰刀菌的MIC/MECs分布范围较广，但F. solani （MEC≤0.12 μg/mL）和F. fujikuroi （MEC≤0.25 μg/mL）除外。基于体外活性，Olorofim可能是治疗镰孢病的良好候选药物。Ibrexafungerp和MGCD290作为单药治疗没有表现出良好的活性。进一步开展针对抗性镰刀菌的应用和新疗法的开发工作至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.